following a full submission
avanafil (Spedra®) is not recommended for use within NHS Scotland.
Indication under review: Treatment of erectile dysfunction (ED) in adult men. In order for avanafil to be effective, sexual stimulation is required.
The pivotal studies demonstrated a statistically significant improvement in ED after administration of avanafil compared with placebo in the general ED population and in patients with ED due to diabetes or following radical prostatectomy.
The submitting company did not present a sufficiently robust clinical and economic analysis to gain acceptance by SMC.
Download detailed advice224KB (PDF)
- Medicine name:
- avanafil (Spedra)
- SMC ID:
- Treatment of erectile dysfunction (ED) in adult men. In order for avanafil to be effective, sexual stimulation is required
- Pharmaceutical company
- A Menarini Pharmaceuticals UK Ltd
- BNF chapter
- Obstetrics, gynaecology, and urinary-tract disorders
- Submission type
- Not recommended
- Date advice published
- 07 September 2015